Comparative evaluation of therapeutic interventions during hemorrhagic shock by Fantoni, Denise Tabacchi et al.
  Universidade de São Paulo
 
2011
 
Comparative evaluation of therapeutic
interventions during hemorrhagic shock
 
 
Critical Care, Londres, v.15, supl.1, p.S32-S33, res.P90, 2011
http://www.producao.usp.br/handle/BDPI/45015
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Cirurgia - FMVZ/VCI Artigos e Materiais de Revistas Científicas - FMVZ/VCI
P1
Eff ects of thyroid hormones on major cardiovascular risk in acute 
coronary syndromes
A Bayrak1, A Bayır2, K Uçar Karabulut3
1Selçuk University, Meram Faculty of Medicine, Konya, Turkey; 2Selçuk 
University, Selçuklu Faculty of Medicine, Emergency Department, Konya, 
Turkey; 3Emergency Sercice of Şırnak State Hospital, Şırnak, Turkey
Critical Care 2011, 15(Suppl 1):P1 (doi: 10.1186/cc9421)
Introduction In this study we aimed to investigate the relationship 
between thyroid hormone abnormalities and major cardiovascular 
events and sudden cardiac death at 3 and 6 months after discharge in 
patients who were admitted to the Emergency Department with acute 
coronary syndrome.
Methods The study group included 110 patients without known 
thyroid dysfunction who were referred to the Emergency Department 
with acute coronary syndrome. FT3, FT4 and TSH levels were measured 
in all patients on admission. Patients were divided into STEMI, NSTEMI 
and UAP groups. Patient records were checked at 3 and 6 months of 
discharge in terms of sudden cardiac death and major cardiovascular 
events. The relationship between thyroid hormone levels and acute 
cardiac death and major cardiovascular disorders at 3 and 6 months of 
discharge was evaluated.
Results The mean TSH, FT3 and FT4 levels of the study group versus 
control group were as follows: TSH levels of study group 1.87 ± 1.73 μIU/
ml, FT3 3.2 ± 1.34 pg/ml, FT4 1.45 ± 0.64 ng/dl. Abnormalities in the 
thyroid function tests were noted in 26 patients (23.6%). Of these seven 
patients (6.36%) had subclinical hypothyroidism, two patients (1.8%) 
had euthyroid sick syndrome and 10 patients (9%) had high serum FT4 
levels despite normal FT3 and TSH values.
Conclusions We noted subclinical hypothyroidism, less frequently 
euthyroid sick syndrome and hyperthyroidism. No relationship was 
noted between thyroid hormone levels and sudden cardiac death and 
major cardiovascular disorders at 3 and 6 months follow-up. However, 
studies including larger patient groups are needed to clarify if there 
is a relationship between thyroid hormone levels on admission and 
sudden death and major cardiovascular events in patients with acute 
coronary syndrome.
References
1. Paulou HN, et al.: Angiology 2002, 53:699-707.
2. Pingitore A, et al.: Am J Med 2005, 118:132-136.
P2
Eff ect of reperfusion therapy on QTd and QTcd in patients with 
acute STEMI
D Ragab, H Elghawaby, M Eldesouky, T Elsayed
Cairo University, Cairo, Egypt
Critical Care 2011, 15(Suppl 1):P2 (doi: 10.1186/cc9422)
Introduction Acute ischemia alters action potentials and aff ects 
myocardial repolarization. Dispersion of repolarization is arrhythmogenic. 
QT dispersion has been suggested to give information about the 
heterogeneity of myocardial repolarization.
Methods Our study included 60 patients presented with acute 
STEMI, the study populations were divided into two groups: Group 
I: 30 patients who underwent primary PCI. Group II: 15 patients who 
received streptokinase. Group III: 15 patients who did not receive 
reperfusion therapy. QTd and QTcd were measured and compared in 
the three groups on admission, after 24 hours and after 5 days.
Results QTd and QTcd were signifi cantly higher in patients with anterior 
compared with inferior MI (79.16 ± 25.67 ms vs. 62 ± 18.17 ms, P = 0.004
regarding QTd and 91.95  ±  28.76 ms vs. 68.33  ±  23.52 ms, P  <0.001 
regarding QTcd). After 24 hours, QTd and QTcd were signifi cantly lower 
in group I than groups II and III (34.33 ± 13.56 ms vs. 48 ± 18.2 ms vs. 
66 ± 24.43 ms respectively, P <0.05 as regards QTd and 39.33 ± 11.72 
ms vs. 56 ± 23.84 ms vs. 74.60 ± 26.7 ms respectively, P <0.05 as regards 
QTcd). On the 5th day reduction in QTd and QTcd was statistically 
signifi cantly lower in group I than groups II and III (23  ±  9.52 ms vs. 
45.33 ± 15.97 ms vs. 58.66 ± 23.25 ms respectively, P <0.05 for QTd and 
26  ±  11.63 ms vs. 52.66  ±  21.2 ms vs. 60.66  ±  23.25 ms respectively, 
P <0.05 for QTcd). QT and QTcd on admission were higher in patients 
who developed ventricular arrhythmias than patients who did not 
(90 ± 11.55 ms vs. 70 ± 24.54 ms; P = 0.05 regarding QTd and 110 ± 8.61 
ms vs. 80.53 ± 28.78 ms with P = 0.028 regarding QTcd). Patients with 
early peaking of enzymes had more reduction in QTd and QTcd early 
after reperfusion (43.2 ± 11.44 vs. 60.5 ± 13.16, P <0.001 regarding QTd 
and 49.60 ± 15.93 vs. 68.5 ± 17.55, P <0.001 regarding QTcd).
Conclusions QTd is higher in patients with acute MI (AMI) who 
developed ventricular arrhythmias. So QTd and QTcd on admission may 
be a helpful parameter that can detect patients with AMI who are at 
risk for development of ventricular arrhythmias. Reperfusion therapy 
with primary PCI or thrombolytic agents reduces QTd and QTcd in 
patients with AMI, however; QTd and QTcd are shorter with primary PCI 
compared with thrombolytic therapy.
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Introduction Myocardial infarction (MI) is a key component of the 
burden of cardiovascular disease (CVD). The main causal and treatable 
risk factors for MI include hypertension, hypercholesterolemia or 
dyslipidemia, diabetes mellitus, and smoking. Acute MI results in 
cellular necrosis with release of constituent proteins into the circulation. 
Measurement of specifi c enzymes has become an important clinical 
tool for the diagnosis and management of MI. The aim of this study was 
to demonstrate the role of arginase and adenosine deaminase (ADA) in 
patients suff ering from MI, and in a group of patients with chronic renal 
failure (CRF) with cardiovascular diseases (CVD).
Methods In this prospective study including 90 consecutive subjects 
were included the MI group (GI) consisting of 30 patients with mean 
age  =  51.7 admitted to critical care medicine (CCM) in Cairo University © 2010 BioMed Central Ltd
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tended to accumulate in the plasma and to cause negative eff ects 
on haemostasis, more recent products (for example, HES 130/0.4) are 
characterised by improved pharmacological properties. The present 
study was designed to compare the effi  cacy and safety of 10% HES 
130/0.4 and 10% HES 200/0.5.
Methods In this post-hoc analysis of a prospective, randomised, 
double-blind, multicenter therapeutic equivalence trial, 76 patients 
undergoing elective on-pump cardiac surgery received perioperative 
volume replacement using either 10% HES 130/0.4 (n = 37) or 10% HES 
200/0.5 (n = 39) up to a maximum dose of 20 ml/kg.
Results Equivalent volumes of investigational medications were 
infused until 24  hours after the fi rst administration (1,577 vs. 
1,540 ml; treatment diff erence 37 [–150; 223] ml; P  <0.0001 for 
equivalence). Whereas standard laboratory tests of coagulation were 
comparable between groups, von Willebrand factor activity on the fi rst 
postoperative morning tended to be higher following treatment with 
10% HES 130/0.4 as compared with 10% HES 200/0.5 (P = 0.025), with 
this diff erence being statistically signifi cant in the per-protocol analysis 
(P = 0.02). Treatment groups were comparable concerning other safety 
parameters and the incidence of adverse drug reactions. In particular, 
renal function was well preserved in both groups.
Conclusions 10% HES 130/0.4 was equally eff ective and safe as 
compared with 10% HES 200/0.5 for volume therapy in patients 
undergoing cardiovascular surgery. Postoperative coagulation and 
renal function, as measured by standard laboratory tests, were similar 
among groups.
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Introduction Continuous exposure to nitrates is associated with 
tachyphylaxis. This study compares the eff ects and tolerance during 
intravenous treatment with nitroglycerin and nicorandil over a 48-hour 
period.
Methods Twenty patients with congestive heart failure and pulmonary 
capillary wedge pressure (PCWP) ≥18 mmHg were randomly assigned 
to nitroglycerin or nicorandil intravenous infusions. Doses were titrated 
to obtain a reduction of PCWP of at least 30% at 6  hours and then 
maintained for 48 hours.
Results There was no statistical diff erence between the groups in terms 
of age, sex, and NYHA grade. The pretreatment PCWP for nitroglycerin 
was 25.7 mmHg, decreasing to 18.4 mmHg at 6 hours. The values for 
nicorandil were 25.4 mmHg and 17.3 mmHg, respectively. There was 
no statistical diff erence between the two groups (P = 0.79 pretreatment 
and 0.23 at 6  hours). The mean PCWP values for 24  hours were 19.7 
and 17.4, respectively, which was statistically signifi cant (P  =  0.036). 
Similarly, the values for 48  hours were 20.6 and 17.9, which was 
signifi cant (P = 0.026) (see Table 1).
Table 1 (abstract P88). PCWP values before and after treatment
Variable Nitroglycerin Nicorandil
Number 10 (8/2) 10 (7/3)
Age 49.9 51.4
Pretreatment 25.7 25.4
6 hours 18.4 17.3
24 hours 19.7 17.4
48 hours 20.6 17.9
Conclusions Intravenous nicorandil administration gives similar 
reductions in PCWP compared with nitroglycerin with signifi cantly 
less haemodynamic tolerance over a 48-hour period compared with 
nitroglycerin. This might represent a clinical advantage of nicorandil 
in the short-term treatment of patients with congestive heart failure.
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Introduction The aim of this meta-analysis is to compare the changes 
in hemodynamic parameters among patients with septic shock who 
have received either of the two agents in their management and try to 
deduce the superiority of one over the other.
Methods A total of 880 articles were identifi ed by a computerized search 
using MEDLINE, OVID and the Cochrane Central Register of Controlled 
Trials, of which six randomised controlled studies were included in 
the study. Observational data, retrospective studies or animal-based 
studies were excluded. Main outcome measures evaluated were the 
changes from the baseline in heart rate, mean arterial pressure, oxygen 
delivery index, oxygen extraction, systemic vascular resistance index 
(SVRI), cardiac index (CI), central venous pressure, blood lactate levels, 
urine output, mean pulmonary artery pressure (MPAP), pulmonary 
capillary wedge pressure, right ventricular ejection fraction (RVEF), 
arrhythmias and 28-day mortality rates. The statistical analysis was 
performed using Comprehensive Meta-Analysis software.
Results No signifi cant diff erence was found in mortality between 
the two groups (RR  =  1.067, CI  =  0.984 to 1.157, P  =  0.115). In the 
norpinephrine group, heart rate was signifi cantly lower in comparison 
with baseline (mean change  =  –16.32 beats/minute, CI  =  –22.23 to 
–10.31, P  <0.001) and so also was the occurrence of arrhythmias 
(RR  =  2.34, CI  =  1.456 to 3.775, P  <0.001). The SVRI, however, was 
signifi cantly higher in this group (diff erence in mean 185 dynes/cm5m2, 
CI = 141.214 to 229.05, P <0.001). Patients who were on dopamine had 
signifi cantly better RVEF% (mean diff erence = 2.38%, CI = 1.058 to 3.671, 
P <0.001) and a lower lactate level (mean diff erence = –0.170 mmol/l, 
CI = –0.331 to –0.009, P = 0.038). Urine output, oxygen delivery, MPAP 
and oxygen consumption were not signifi cantly diff erent between the 
two groups.
Conclusions Patients who received dopamine had a better right 
ventricular ejection fraction, lower lactate levels, lower systemic 
vascular resistance index and a trend towards a better cardiac index. 
However, this group was noted to have more arrhythmias and a higher 
baseline heart rate versus the norepinephrine group. Overall, there 
was no diff erence in the 28-day mortality between the two groups. 
Although there are certain hemodynamic advantages, we were unable 
to deduce the superiority of one pressor. The results support the 
current practice of individualizing the choice of an initial vasopressor 
based on patient profi le.
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Introduction Resuscitation of patients with hemorrhagic shock (HS) 
represents a challenge in emergency medicine. The uncontrollable 
bleeding and subsequent cardiovascular collapse are responsible for 
40% of the early mortality rate in trauma.
Methods Twelve Large White pigs at 5 months of age, weighing 25 kg, 
were submitted to a surgical procedure for liver resection or autologous 
liver transplantation. Ketamine S+ (5  mg/kg, i.m.) and midazolam 
(0.5 mg/kg, i.m.) were used as a premedicant. Anesthesia was induced 
with propofol (3  mg/kg, i.v.) and maintained with 1.5% isofl urano 
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end-tidal concentration and volume-controlled ventilation (8 ml/kg) on 
40% inspired oxygen fraction. Analgesia and neuromuscular blockade 
were accomplishments with continuous infusion of fentanyl (0.4 mg/
kg/minute) and pancuronium (0.3  mg/kg/hour). The shock was 
diagnosed when blood loss exceeds 40% of the total blood volume. 
The HS results in mean arterial pressure reduce (MAP ≤50 mmHg), 50% 
cardiac output reduction (CO) and central venous saturation (SvO2) 
decreased to 70 mmHg. The animals underwent hemodynamic, arterial 
blood gases and venous monitoring, at baseline (t0), impact moment 
(t1), after treatment (t2), intervals of 15 minutes after shock treatment 
(t3, t4, t5, t6), and 120 minutes after treatment (t7). Subsequent to shock 
diagnosis, the animals were randomly divided into GI treated with 
vasopressin (0.01 IU/kg/minute), norepinephrine (0.3  mg/kg/minute) 
and Ringer’s lactate solution (aliquots of 20 ml/kg/20 minutes until 
MAP >60 mmHg). GII was equal to GI but ringer lactate administration 
was replaced during 20 minutes of whole blood stored during 10 days 
at half blood loss volume.
Results See Table 1. Both groups showed a signifi cant parameter 
decrease during hemorrhagic shock (t1) compared with t0. After 
treatment GI showed improvements in all parameters, GII showed 
improvement until t3. During t4 the animals presented a signifi cant 
increase in K levels, lactate and decreased SvO2, CO, MAP followed by 
an increase in SvO2 (89%). The diff erences between the two groups 
and moments were statistically signifi cant (P >0.01). GII had a 50% 
of mortality rate between t4 and t5 related with potassium increase. 
Subsequent to animal blood treatment, the patients showed an 
increase in T wave, ventricular fi brillation and death.
Table 1 (abstract P90)
 CO MAP SvO2 PAP K Lactate
 (l/min)  (mmHg)  (%)  (mmHg)  (mmol/l)  (mg/dl)
t0 GI 3.6 ± 0.4 86 ± 10 75 ± 3 18 ± 2 3.5 ± 0.4 19 ± 8
t1 GI 1.3 ± 0.3 48 ± 10 58 ± 5 8 ± 3 4 ± 0.3 47 ± 8
t0 GII 4 ± 0.4 84 ± 8 76 ± 3 20 ± 3 4 ± 0.2 20 ± 10
t2 GII 1.5 ± 0.5 44 ± 5 57 ± 3 10 ± 2 4.3 ± 0.3 50 ± 108
Conclusions It is possible to conclude that whole blood replacement in 
animals with HS should be slow and steady to avoid the eff ects of high 
K administration during a short period. Those therapeutic interventions 
are indicated to avoid the consequences of HS.
Reference
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Introduction Arginine vasopressin (AVP) and terlipressin (TP) are 
increasingly used to stabilize mean arterial pressure in the setting of 
septic shock. Whether these vasopressor agents negatively impact on 
microcirculatory perfusion is still not fully understood. The objective 
of the present study was, therefore, to elucidate the eff ects of AVP 
and TP on microcirculatory perfusion in patients with catecholamine-
dependent septic shock.
Methods We enrolled 60 fl uid-resuscitated septic shock patients 
requiring norepinephrine (NE) to maintain mean arterial pressure 
(MAP) between 65 and 75 mmHg. Patients were randomly allocated to 
be treated with either continuous TP infusion (1 μg/kg/hour), or AVP 
(0.04 U/minute), or titrated NE (control; each n  =  20). In both the TP 
and AVP groups, NE was titrated to achieve a MAP between 65 and 
75 mmHg. Data from right heart catheterization and sidestream dark-
fi eld imaging were obtained at baseline and after 6 hours.
Results No signifi cant diff erences were found between groups in terms 
of MAP, cardiac index, mixed-venous oxygen saturation, arterial lactate, 
and microvascular fl ow index of the small vessels (2.1 (1.8; 2.4) vs. 3.0 
(2.6; 3.0) for TP, 1.9 (1.7; 2.3) vs. 2.7 (2.0; 3.0) for AVP, 2.3 (2.1; 2.6) vs. 
3.0 (2.9; 3.0) for NE). Conversely, AVP and TP signifi cantly reduced NE 
requirements over time (0.57 (0.29; 1.04) vs. 0.16 (0.03; 0.37) μg/kg/
minute for TP and 0.40 (0.20; 1.05) vs. 0.23 (0.03; 0.77) μg/kg/minute for 
AVP; all P <0.05). However, no diff erences were found between TP and 
AVP after 6 hours.
Conclusions The results of the present study suggest that vaso-
pressinergic V1 agonists allow a reduction in catecholamine require-
ments without negative impact on microvasular perfusion as compared 
with sole NE therapy.
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Introduction We examine benefi ts and risks of vasopressin/terlipressin 
use in patients with vasodilatory shock on mortality and morbidity.
Methods We searched the CENTRAL, MEDLINE, Embase, and LILACS 
(through to August 2010) databases. Randomized and quasi-
randomized trials of vasopressin/terlipressin versus placebo or suppor-
tive treatment in adult and pediatric patients with vasodilatory shock 
were included. The primary outcome for this review was short-term all-
cause mortality.
Results We computed data from 10 randomized trials (n = 1,111). The 
overall (28-day, 30-day, ICU, hospital and 24-hour) mortality for those 
treated with vasopressin and terlipressin versus control patients was 
237 of 582 (40.7%) versus 226 of 528 (42.8%) (RR, 0.92; 95% CI, 0.81 to 
Figure 1 (abstract P92). Overall mortality.
Figure 2 (abstract P92). Norepinephrine dosage.
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